The Second Academic Committee Meeting of the Joint Engineering Center for Tetrahedral Framework Nucleic Acids Successfully Held

On the afternoon of June 28, the Second Academic Committee Meeting of the Joint Engineering Center for Tetrahedral Framework Nucleic Acids (TFNA) in 2025 was successfully held at Yunhai Bio.

Attendees included: Academician Chunhai Fan of the Chinese Academy of Sciences; Fellow of the National Academy of Inventors (USA) Ye Hu; Deputy Secretary of the Party Committee of West China School of Stomatology, Sichuan University, Professor Yunfeng Lin; Editor-in-Chief of Nature Biomedical Engineering, Pep Pàmies; Professor Quanyi Guo from the Department of Orthopedics, General Hospital of the People’s Liberation Army (PLA); Professor Yanping Song from the Ophthalmology Department of the PLA Central Theater Command General Hospital; Professor Xiaoyan Ding from Zhongshan Ophthalmic Center, Sun Yat-sen University; Editor of Cell Biomaterials, Yuan Chu; Chairman of Chuangjian Medical, Song Qian; Professor Jian Huang from the University of Electronic Science and Technology of China; President of Yunhai Bio, Delun Luo; Chairman of Yunhai Bio, Yang Yu; and Vice Presidents Rong Li and Ben Wang of Yunhai Bio.

The meeting began with welcoming remarks from Academician Chunhai Fan and Academician Ye Hu on behalf of the Academic Committee. The successful convening of the second committee meeting at Yunhai Bio highlights the accelerating momentum of TFNA technology in the biomedical field. This year’s meeting focused on critical challenges and frontier directions in technology translation, aiming to establish an in-depth communication platform for collaboration across industry, academia, and research.

Over the past year, the TFNA technology has achieved breakthrough results in three key areas: ophthalmology, neurological disorders, and skin health. Attending academicians and experts engaged in dynamic discussions on the application prospects of TFNAs in nucleic acid drug delivery, diagnosis and treatment of eye diseases, and tissue regeneration.

Participants also toured the headquarters of the Joint Engineering Center for Tetrahedral Framework Nucleic Acids—Chengdu Yunhai Tetrahedral Framework Biotechnology Co., Ltd. There, they gained an in-depth understanding of how Yunhai Bio is leveraging its independently developed TFNA platform through a model of "patent operation + industry-academia-research collaboration" to drive full-chain translation of TFNA technology in the fields of nucleic acid therapeutics, medical aesthetics, and beyond.